Anebulo Pharmaceuticals Inc 2025年季度报告

FORM10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember 30, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File No.001-40388 ANEBULO PHARMACEUTICALS, INC.(Exact name of registrant as specified in its charter) Delaware85-1170950(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.) 1017 Ranch Road 620 South,Suite 107Lakeway,Texas78734(Address of principal executive offices)(Zip Code) (512)598-0931(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of November 7, 2025, the registrant had41,084,731shares of common stock, par value $0.001per share, outstanding. Anebulo Pharmaceuticals, Inc.Table of Contents Special Note Regarding Forward-Looking StatementsPART I. FINANCIAL INFORMATIONItem 1. Financial Statements (Unaudited)1Condensed Balance Sheets as of September 30, 2025 and June 30, 20251Condensed Statements of Operations for the Three Months Ended September 30, 2025 and 20242Condensed Statements of Stockholders’ Equity for the Three Months Ended September 30, 2025 and 20243Condensed Statements of Cash Flows for the Three Months Ended September 30, 2025 and 20244Notes to Unaudited Condensed Financial Statements5Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations11Item 3. Quantitative and Qualitative Disclosures About Market Risk21Item 4. Controls and Procedures21PART II. OTHER INFORMATIONItem 1. Legal Proceedings22Item 1A. Risk Factors22Item 2. Unregistered Sales of Equity Securities and Use of Proceeds27Item 3. Defaults Upon Senior Securities27Item 4. Mine Safety Disclosures27Item 5. Other Information27Item 6. Exhibits28Signatures29 In this report, unless otherwise stated or as the context otherwise requires, references to “Anebulo Pharmaceuticals,” “Anebulo,”“Company,” “we,” “us,” “our” and similar references refer to Anebulo Pharmaceuticals, Inc. The Anebulo logo, and other trademarksor service marks of Anebulo Pharmaceuticals, Inc. appearing in this report are the property of Anebulo Pharmaceuticals, Inc. Thisreport also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks andtrade names appearing in this report are the property of their respective holders. We do not intend our use or display of othercompanies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these othercompanies. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains “forward-looking statements” within the meaning ofSection 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934,as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections. These forward-looking statementsabout us and our industry involve substantial risks and uncertainties and our actual results could differ materially from thoseanticipated in these forward-looking statements as a result of various factors, including those set forth below under Part II, Item 1A,“Risk Factors” in this Quarterly Report and the “Risk Factors” as set forth i